Ben Glenn, Dev Kurkidar, Shar Matin, Paul Snyder and Tiffany Wilson shared their insights into “De-Risking Medtech Innovation by Investing in the Process Before the Product,” with more than 100 early and emerging-growth medical technology executives seeking to bring their innovations to market.
“Is Getting New Treatments to Patients Harder Than Landing on Mars?” Georgia Tech Research Horizons Senior Science Writer, Ben Brumfield, recently enlisted GCMI CEO, Tiffany Wilson, to help answer the question. According to the article, only 15% of new therapies make it to patients, and getting a new treatment to market can require $1 billion in pharmaceutical company investment, “more than the entire budget for the latest NASA Mars mission.”